Genocea Biosciences, Inc.
GNCA
GNCA was delisted on the 2nd of June, 2022.
61 hedge funds and large institutions have $88.7M invested in Genocea Biosciences, Inc. in 2017 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 18 increasing their positions, 6 reducing their positions, and 10 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 6
120% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 10
24% more funds holding
Funds holding: 49 → 61 (+12)
6% less capital invested
Capital invested by funds: $94M → $88.7M (-$5.32M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
99% less call options, than puts
Call options by funds: $1K | Put options by funds: $69K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$6.89M |
| 2 |
State Street
Boston,
Massachusetts
|
+$2.07M |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$1.6M |
| 4 |
NC
Northpointe Capital
Bloomfield Hills,
Michigan
|
+$706K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$631K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$2.92M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.36M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$940K |
| 4 |
Millennium Management
New York
|
-$321K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$271K |
GNCA Hedge Fund Activity: Q2 2017 in Review
61 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Genocea Biosciences, Inc. (GNCA) for Q2 2017, worth a combined $88.7M — down 5.7% from $94M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new GNCA positions and 10 closed out — a net gain of 12 holders — while 18 added to existing stakes and 6 trimmed.
The largest buyer was BlackRock, adding an estimated $6.89M. The largest seller was Deerfield Management, exiting entirely with an estimated $2.92M sold.
- 61 institutional investors held Genocea Biosciences, Inc. (GNCA) as of Q2 2017, up from 49 in Q1 2017.
- Funds reported $88.7M of Genocea Biosciences, Inc. stock for Q2 2017, down 5.7% quarter-over-quarter.
- 22 funds opened new Genocea Biosciences, Inc. positions in Q2 2017 and 10 closed out, a net change of +12 holders.
- The largest Genocea Biosciences, Inc. buyer in Q2 2017 was BlackRock, an estimated $6.89M added.
- The largest Genocea Biosciences, Inc. seller in Q2 2017 was Deerfield Management, an estimated $2.92M sold.
Based on aggregated 13F filings for Q2 2017.